Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience
- PMID: 21325599
- DOI: 10.1182/blood-2010-10-312082
Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience
Abstract
Children with primary immunodeficiency diseases, particularly those less than 1 year of age, experience significant toxicity after hematopoietic stem cell transplantation, with busulfan- or melphalan-based conditioning. Treosulfan causes less veno-occlusive disease than busulfan and does not require pharmacokinetic monitoring. We report its use in 70 children. Children received 42 g/m(2) or 36 g/m(2) with cyclophosphamide 200 mg/kg (n = 30) or fludarabine 150 mg/m(2) (n = 40), with alemtuzumab in most. Median age at transplantation was 8.5 months (range, 1.2-175 months); 46 (66%) patients were 12 months of age or younger. Donors were as follows: matched sibling donor, 8; matched family donor, 13; haploidentical, 4; and unrelated, 45. Median follow-up was 19 months (range, 1-47 months). Overall survival was 81%, equivalent in those age less or greater than 1 year. Skin toxicity was common. Veno-occlusive disease occurred twice with cyclophosphamide. Eighteen patients (26%) had graft-versus-host disease, and only 7 (10%) greater than grade 2. Two patients rejected; 24 of 42 more than 1 year after transplantation had 100% donor chimerism. The remainder had stable mixed chimerism. T-cell chimerism was significantly better with fludarabine. Long-term follow-up is required, but in combination with fludarabine, treosulfan is a good choice of conditioning for hematopoietic stem cell transplantation in primary immunodeficiency disease.
Similar articles
-
Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience.Biol Blood Marrow Transplant. 2018 Mar;24(3):529-536. doi: 10.1016/j.bbmt.2017.11.009. Epub 2017 Nov 16. Biol Blood Marrow Transplant. 2018. PMID: 29155317 Clinical Trial.
-
Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.Cancer. 2017 Jul 15;123(14):2671-2679. doi: 10.1002/cncr.30646. Epub 2017 Mar 22. Cancer. 2017. PMID: 28329410
-
European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.Pediatr Blood Cancer. 2016 Jan;63(1):139-48. doi: 10.1002/pbc.25764. Epub 2015 Sep 23. Pediatr Blood Cancer. 2016. PMID: 26398915
-
Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike.Bone Marrow Transplant. 2012 Jan;47(1):5-14. doi: 10.1038/bmt.2011.88. Epub 2011 Apr 11. Bone Marrow Transplant. 2012. PMID: 21478921 Review.
-
Conditioning Regimens for Hematopoietic Cell Transplantation in Primary Immunodeficiency.Curr Allergy Asthma Rep. 2019 Nov 18;19(11):52. doi: 10.1007/s11882-019-0883-1. Curr Allergy Asthma Rep. 2019. PMID: 31741098 Free PMC article. Review.
Cited by
-
Fatal outcome despite full lympho-hematopoietic reconstitution after allogeneic stem cell transplantation in atypical ataxia telangiectasia.J Clin Immunol. 2012 Jun;32(3):438-40. doi: 10.1007/s10875-012-9654-7. Epub 2012 Feb 23. J Clin Immunol. 2012. PMID: 22354567
-
Treosulfan-based conditioning for inborn errors of immunity.Ther Adv Hematol. 2021 May 20;12:20406207211013985. doi: 10.1177/20406207211013985. eCollection 2021. Ther Adv Hematol. 2021. PMID: 34094045 Free PMC article. Review.
-
Postpartum HLA-Matched Bone Marrow Donation from Mother to Neonate for Reticular Dysgenesis.J Clin Immunol. 2017 Jan;37(1):29-31. doi: 10.1007/s10875-016-0355-5. Epub 2016 Dec 3. J Clin Immunol. 2017. PMID: 27913909 No abstract available.
-
Immune Reconstitution after Hematopoietic Stem Cell Transplantation in Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome Type 1.J Clin Immunol. 2021 Jul;41(5):1089-1094. doi: 10.1007/s10875-021-00984-x. Epub 2021 Feb 5. J Clin Immunol. 2021. PMID: 33544358 Free PMC article. No abstract available.
-
T cell depletion in paediatric stem cell transplantation.Clin Exp Immunol. 2013 May;172(2):139-47. doi: 10.1111/cei.12004. Clin Exp Immunol. 2013. PMID: 23574311 Free PMC article. Review.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
